Atypical antipsychotics: Part II: Adverse effects, drug interactions, and costs

OBJECTIVE: To compare the adverse effects, drug interactions, and costs of conventional and atypical agents, and to provide a summary of therapeutic guidelines. Part I compared the pharmacology, pharmacokinetics, and efficacy of atypical and conventional agents. DATA SOURCES: Information was retrieved from a MEDLINE English-language literature search from June 1986 to June 1998 and by review of references. Indexing terms included atypical antipsychotics, neuroleptics, clozapine, risperidone, olanzapine, sertindole, quetiapine, and ziprasidone. STUDY SELECTION: Comparative studies were selected when possible; placebo-controlled studies were included when data were limited on newer atypical antipsychotics. DATA EXTRACTION: Emphasis was placed on properly designed clinical trials that assessed dosage, expanded efficacy, enhanced adverse effect profile, and cost. DATA SYNTHESIS: Significant adverse effects are agranulocytosis with clozapine, dose-dependent extrapyramidal side effects (EPS) with risperidone, and neuroleptic malignant syndrome with clozapine and risperidone. Clinically relevant drug interactions may occur with clozapine-lorazepam, clozapine-fluvoxamine, and sertindole-quinidine. Newer atypical agents have high acquisition costs but may reduce noncompliance and rehospitalization rates. CONCLUSIONS: Risperidone or olanzapine are recommended as first-line agents for schizophrenia due to accumulating controlled trials and clinical experience. Quetiapine should be considered with partial response or if EPS develop, and clozapine is an option with treatment-refractory patients. Atypical agents may contribute to a better quality of life, but conventional neuroleptics are the first choice for strictly cost considerations.

This article has been cited by other articles:

				J. S. Markowitz, C. L. DeVane, R. J. Malcolm, H. A. Gefroh, J.-S. Wang, H.-J. Zhu, and J. L. Donovan Pharmacokinetics of Olanzapine After Single-Dose Oral Administration of Standard Tablet Versus Normal and Sublingual Administration of an Orally Disintegrating Tablet in Normal Volunteers J. Clin. Pharmacol., February 1, 2006; 46(2): 164 - 171. [Abstract] [Full Text] [PDF]

				G. M. Simpson, I. D. Glick, P. J. Weiden, S. J. Romano, and C. O. Siu Randomized, Controlled, Double-Blind Multicenter Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients With Schizophrenia or Schizoaffective Disorder Am J Psychiatry, October 1, 2004; 161(10): 1837 - 1847. [Abstract] [Full Text] [PDF]

				J. M. Kane, M. Eerdekens, J.-P. Lindenmayer, S. J. Keith, M. Lesem, and K. Karcher Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical Antipsychotic Am J Psychiatry, June 1, 2003; 160(6): 1125 - 1132. [Abstract] [Full Text] [PDF]

				M L. Crismon, A. DeLeon, and A. L Miller Aripiprazole: Does Partial Dopaminergic Agonism Translate into Clinical Benefits? Ann. Pharmacother., May 1, 2003; 37(5): 738 - 740. [Full Text] [PDF]

				Q. Zhao, C. Xie, L. Pesco-Koplowitz, X. Jia, and J.-L. Parier Pharmacokinetic and Safety Assessments of Concurrent Administration of Risperidone and Donepezil J. Clin. Pharmacol., February 1, 2003; 43(2): 180 - 186. [Abstract] [Full Text] [PDF]

				D. L. Leslie and R. A. Rosenheck From Conventional to Atypical Antipsychotics and Back: Dynamic Processes in the Diffusion of New Medications Am J Psychiatry, September 1, 2002; 159(9): 1534 - 1540. [Abstract] [Full Text] [PDF]